Literature DB >> 34044855

Hyaluronic acid-lipid binding.

Anthony Ewurum1, Abhishek Ashok Alur2, Margaret Glenn2, Abigail Schnepf1, Douglas Borchman3.   

Abstract

BACKGROUND: Phospholipid (PL)-hyaluronic acid (HA) interactions are relevant to aging-associated vitreous humor liquefaction, therapies for dry eye disease, skin-care products and synovial joint lubrication. Phosphatidyl choline-HA interactions have been well characterized. However, other major lipids found in tears, vitreous humor and synovial joints have not. The purpose of this study was to bridge this gap of knowledge.
METHODS: HA (1600 kDa) at 5 mg/mL, was mixed with various lipids ranging in concentration from 0.1 to 10 mg/mL in D2O. HA-PL binding was measured from the decrease in HA proton resonance intensity with binding using a nuclear magnetic resonance spectrometer.
RESULTS: Cholesterol weakly bound to HA, followed by monoglyceride and palmitoyl palmitate < phosphatidyl choline, phosphatidic acid and sphingomyelin. The maximum amount of PL bound was 14 ± 1 µmoles inferring a 1 to 1 molar ratio of bound PL to HA dimer. Monoglyceride and palmitoyl palmitate required two to three times more lipid to achieve 100% bound HA compared to PL.
CONCLUSIONS: Physiological levels of HA, phosphatidyl choline and sphingomyelin would result in only 4% of the hydrophobic hydrogens of HA to be bound. HA-PL binding interactions could be important for therapeutic use of HA in eye drops in future studies to treat dry eye and to trap PL entering the VH to keep them from forming light scattering micelles. HA-lipid binding may also be relevant to the therapeutic effects of topical skin-care products. Both head group and hydrocarbon chain moieties influence HA-lipid interactions.

Entities:  

Keywords:  Dye eye; Hyaluronan; Liquefaction; Nuclear magnetic resonance; Phospholipids; Vitreous humor

Year:  2021        PMID: 34044855     DOI: 10.1186/s13065-021-00763-0

Source DB:  PubMed          Journal:  BMC Chem        ISSN: 2661-801X


  31 in total

1.  Hyaluronate in normal human synovial fluid.

Authors:  D HAMERMAN; H SCHUSTER
Journal:  J Clin Invest       Date:  1958-01       Impact factor: 14.808

2.  The physiological function of hyaluronic acid in synovial fluid; viscous, elastic and lubricant properties.

Authors:  A G OGSTON; J E STANIER
Journal:  J Physiol       Date:  1953-02-27       Impact factor: 5.182

Review 3.  Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment.

Authors:  A Fakhari; C Berkland
Journal:  Acta Biomater       Date:  2013-03-15       Impact factor: 8.947

4.  Lipids of ocular tissues. I. The phospholipids of mature rabbit and bovine lens.

Authors:  R E Anderson; M B Maude; G L Feldman
Journal:  Biochim Biophys Acta       Date:  1969-10-28

Review 5.  Hyaluronan in skin.

Authors:  L Juhlin
Journal:  J Intern Med       Date:  1997-07       Impact factor: 8.989

6.  Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease.

Authors:  Doreen Schmidl; Leopold Schmetterer; Katarzyna J Witkowska; Angelika Unterhuber; Valentin Aranha dos Santos; Semira Kaya; Johannes Nepp; Carina Baar; Peter Rosner; René M Werkmeister; Gerhard Garhofer
Journal:  Cornea       Date:  2015-04       Impact factor: 2.651

Review 7.  Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications.

Authors:  Grigorij Kogan; Ladislav Soltés; Robert Stern; Peter Gemeiner
Journal:  Biotechnol Lett       Date:  2006-11-08       Impact factor: 2.461

8.  Capstan-like mechanism in hyaluronan-phospholipid systems.

Authors:  P Bełdowski; N Kruszewska; S Yuvan; Z Dendzik; T Goudoulas; A Gadomski
Journal:  Chem Phys Lipids       Date:  2018-08-23       Impact factor: 3.329

9.  Molecular mechanisms of posterior vitreous detachment.

Authors:  J Akiba; N Ueno; B Chakrabarti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-07       Impact factor: 3.117

10.  Use of preservative-free hyaluronic acid (Hylabak(®)) for a range of patients with dry eye syndrome: experience in Russia.

Authors:  Vladimir Vsevolodovich Brjesky; Yury Fedorovich Maychuk; Alexey Vladimirovich Petrayevsky; Peter Gerrievich Nagorsky
Journal:  Clin Ophthalmol       Date:  2014-06-18
View more
  1 in total

1.  Smart Lipid-Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells.

Authors:  Manuela Curcio; Matteo Brindisi; Giuseppe Cirillo; Luca Frattaruolo; Antonella Leggio; Vittoria Rago; Fiore Pasquale Nicoletta; Anna Rita Cappello; Francesca Iemma
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.